Overview#
Capricor Therapeutics Inc (NASDAQ:CAPR) saw its stock price jump by 14.3% on Tuesday. This surge followed the announcement that the U.S. Food and Drug Administration (FDA) has lifted a previous Complete Response Letter and resumed its review of the company’s Biologics License Application (BLA) for Deramiocel. This investigational cell therapy targets Duchenne muscular dystrophy cardiomyopathy, a serious heart condition associated with a genetic disorder.
FDA Review Details#
The FDA has categorized this submission as a Class 2 resubmission. This classification indicates that the review process will take a standard amount of time, with a target action date set for August 22, 2026. Importantly, the FDA has not flagged any potential issues with the review, which is a positive sign for the company.
Clinical Trial Support#
The BLA for Deramiocel is backed by encouraging results from the pivotal HOPE-3 Phase 3 clinical trial. This trial successfully met its primary endpoint and all secondary endpoints that were controlled for Type I errors. If approved, Deramiocel could be the first therapy to effectively treat both the skeletal and cardiac symptoms of Duchenne muscular dystrophy.
Future Prospects#
Capricor previously received a Complete Response Letter from the FDA in July 2025. After submitting additional data from the HOPE-3 trial, the FDA decided to continue its review. The company anticipates that, if Deramiocel is approved, it may qualify for a Priority Review Voucher. This voucher program, which was recently extended by Congress, aims to expedite the approval process for therapies targeting rare pediatric diseases. Analysts have noted that the recent changes in FDA leadership may also positively influence the approval chances for Deramiocel.